thebiostories

How WEHI Scientists Are Helping Defeat Malaria: From Fundamental Discovery to New Treatments ⏱ In 30 Seconds ✓ Malaria remains a major global health threat because parasites and mosquitoes continue to evolve resistance to existing control measures. ✓ For more than three decades, WEHI scientists have studied how malaria parasites invade, survive and reproduce inside human cells. ✓ These fundamental discoveries have revealed new biological vulnerabilities that can guide the development of medicines and vaccines. ✓ One result of this long research journey is MK-7602 , a first-in-class experimental antimalarial drug that has progressed into human clinical trials. Why Malaria Still Matters Malaria has been one of humanity’s deadliest infectious diseases for thousands of years. Although remarkable progress has been made over the past two decades, the disease still causes hundreds of thousands of deaths each year, with young children in sub-Saharan Africa carrying th...

🌏 Available in: English | 한국어 생명을 구한 발견에서 치료 표적으로 GM-CSF 이야기 ⏱ 30초 요약 ✓ GM-CSF 는 처음에는 백혈구의 생성과 기능을 돕는 성장인자로 발견되었습니다. ✓ 이후 연구를 통해 GM-CSF는 대식세포와 단핵구를 비롯한 다양한 면역세포의 염증 반응을 조절하는 중요한 사이토카인이라는 사실이 밝혀졌습니다. ✓ 이러한 발견은 류마티스관절염과 같은 염증성 질환에서 GM-CSF 또는 그 수용체를 차단하는 치료제 개발로 이어졌습니다. ✓ GM-CSF의 이야기는 하나의 분자가 어떤 상황에서는 생명을 구하는 치료제가 되고, 또 다른 상황에서는 치료 표적이 될 수 있음을 보여주는 대표적인 사례입니다. 호주의 과학자 도널드 메트칼프(Don Metcalf) 와 그의 동료들이 과립구-대식세포 집락자극인자(Granulocyte-Macrophage Colony-Stimulating Factor, GM-CSF) 를 발견했을 때, 그리고 G-CSF와 같은 다른 집락자극인자들을 연구했을 때만 해도, 연구자들은 이것이 백혈구 생성을 조절하는 또 하나의 성장인자라고 생각했습니다. 당시로서는 그 해석이 완전히 맞는 것처럼 보였습니다. GM-CSF는 골수에서 과립구와 대식세포의 생성을 촉진하여 항암화학요법이나 골수이식 후 감소한 면역세포를 회복시키는 분자로 이해되었습니다. 실제로 GM-CSF는 뛰어난 임상적 가능성을 보여주었습니다. 세계적인 테너 호세 카레라스(José Carreras)는 백혈병 치료 과정에서 GM-CSF가 사용된 초기 임상시험에 참여했고, 이는 혈액세포 생물학의 기초 연구가 실제 환자의 생명을 살리는 치료로 이어질 수 있음을 보여주는 대표적인 사례가 되었습니다. GM-CSF에 대한 연구가 계속되면서 백혈구 생성 이외의 역할도 밝혀지기 시작했습니다. 많은 염증성 질환에서는 면역세포의 수뿐 아니라 이들 세포의 행동에도 변화가 나타났습니다. 이들...

🌏 Available in: English | 한국어 From Life-Saving Discovery to Drug Target The Story of GM-CSF ⏱ In 30 Seconds ✓ GM-CSF was first discovered as a growth factor that supports the production and function of white blood cells. ✓ It later became clear that GM-CSF also changes how macrophages, monocytes and other immune cells behave during inflammation. ✓ This led scientists to develop antibodies that block GM-CSF or its receptor in diseases such as rheumatoid arthritis. ✓ The story shows how the same biological pathway can help patients in one setting but become a therapeutic target in another. When Australian scientist Professor Don Metcalf and his colleagues first discovered granulocyte-macrophage colony-stimulating factor (GM-CSF) , together with other colony-stimulating factors such as G-CSF , they believed they had identified another growth factor involved in white blood cell production. For years, that assumption appeared to be correct. GM-CSF was...

🌏 Available in: English | 한국어 Frank Macfarlane Burnet: The Nobel Prize Winner Who Shaped Modern Immunology ⏱ In 30 Seconds ✓ Frank Macfarlane Burnet helped transform modern immunology through the theory of clonal selection . ✓ His ideas helped explain how the immune system distinguishes the body’s own tissues from foreign threats. ✓ Burnet shared the 1960 Nobel Prize in Physiology or Medicine for work on acquired immunological tolerance. ✓ His research helped establish the conceptual foundations of transplantation, autoimmune disease research and modern immune-based medicine. When people think of famous Australian scientists, names such as Howard Florey, Peter Doherty and Elizabeth Blackburn may come to mind first. Frank Macfarlane Burnet is less familiar to the general public, but his influence on modern immunology is difficult to overstate. Burnet did not discover a blockbuster drug. Instead, he helped explain one of the most fundamental pro...

🌏 Available in: English | 한국어 An Australian Discovery Reveals a Dysregulated Immune Pathway in Acute Rheumatic Fever How a common bacterial infection can trigger persistent inflammation and lifelong heart-valve damage ⏱ In 30 Seconds ✓ Acute rheumatic fever can develop after infection with Group A Streptococcus and may eventually cause permanent heart-valve damage. ✓ Australian researchers identified a dysregulated IL-1β–GM-CSF immune pathway in cells from people with acute rheumatic fever. ✓ IL-1β promoted the expansion of inflammatory GM-CSF-producing CD4 T cells , offering a possible explanation for persistent immune activation. ✓ The study also showed that hydroxychloroquine could suppress this response in laboratory experiments, suggesting a potential direction for future immune-targeted therapies. Every year, hundreds of millions of people are infected with Group A Streptococcus , commonly known as GAS. For most people, the infection causes a...

🌏 Available in: English | 한국어 Hidden Heroes to Modern Medicine: The Mice Behind Medical Breakthroughs Long before a new treatment reaches its first patient, the scientific journey often begins with a carefully designed mouse model. ⏱ In 30 Seconds ✓ Mouse models allow researchers to study how genes, cells and biological pathways contribute to disease inside a living organism. ✓ Mice share many genes and biological processes with humans, while their genomes can be precisely modified to test cause and effect. ✓ Knockout, transgenic, conditional, reporter, humanised and patient-derived tumour models are designed to answer different scientific questions. ✓ Mouse models have contributed to major advances in cancer biology, immunology, infectious disease, blood-cell development and genetic disease. ✓ Mice are not miniature humans, so findings from mouse models must ultimately be tested against human biology and clinical evidence. Mouse models have played an...

🌏 Available in: English | 한국어 How Was Venetoclax Developed? The Australian Story Behind a Breakthrough Cancer Therapy ⏱ In 30 Seconds ✓ Venetoclax is a targeted cancer medicine that blocks BCL-2 , a protein that helps some cancer cells survive. ✓ Its development grew from decades of fundamental research into programmed cell death, or apoptosis . ✓ Scientists at WEHI played a key role in transforming BCL-2 from a biological discovery into a therapeutic target. ✓ Venetoclax is now used to treat several blood cancers, including chronic lymphocytic leukaemia and acute myeloid leukaemia . A Personal Note During my years at WEHI, I had the chance to see the later stages of the Venetoclax story unfolding around me, as clinical trials progressed and decades of research moved towards a treatment that could actually reach patients. I knew at the time that it was an important scientific achievement. But recently, I happened to read blogs where people with bl...